These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 36505475)

  • 21. Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses.
    Pacheco-Olvera DL; Saint Remy-Hernández S; García-Valeriano MG; Rivera-Hernández T; López-Macías C
    Arch Med Res; 2022 Nov; 53(7):694-710. PubMed ID: 36336501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
    Li Y; Wang X; Jin J; Ma Z; Liu Y; Zhang X; Su B
    J Med Virol; 2022 Aug; 94(8):3998-4004. PubMed ID: 35474581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam.
    Nguyen TTN; Choo EM; Nakamura Y; Suzuki R; Shiina T; Shin-I T; Fukuta M; Nguyen CT; Nguyen TTT; Nguyen LKH; Hoang VMP; Morita K; Dang DA; Hasebe F; Le TQM; Moi ML
    Int J Infect Dis; 2024 Feb; 139():109-117. PubMed ID: 37984763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-protection induced by highly conserved human B, CD4
    Prakash S; Dhanushkodi NR; Zayou L; Ibraim IC; Quadiri A; Coulon PG; Tifrea DF; Suzer B; Shaik AM; Chilukuri A; Edwards RA; Singer M; Vahed H; Nesburn AB; Kuppermann BD; Ulmer JB; Gil D; Jones TM; BenMohamed L
    Front Immunol; 2024; 15():1328905. PubMed ID: 38318166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies.
    Ling Z; Yi C; Sun X; Yang Z; Sun B
    Sci China Life Sci; 2023 Apr; 66(4):658-678. PubMed ID: 36443513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
    Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development.
    Magazine N; Zhang T; Bungwon AD; McGee MC; Wu Y; Veggiani G; Huang W
    Immunohorizons; 2024 Mar; 8(3):214-226. PubMed ID: 38427047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
    Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
    Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
    Mittal A; Khattri A; Verma V
    PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep immunoglobulin repertoire sequencing depicts a comprehensive atlas of spike-specific antibody lineages shared among COVID-19 convalescents.
    Yan Q; Zhang Y; Hou R; Pan W; Liang H; Gao X; Deng W; Huang X; Qu L; Tang C; He P; Liu B; Wang Q; Zhao X; Lin Z; Chen Z; Li P; Han J; Xiong X; Zhao J; Li S; Niu X; Chen L
    Emerg Microbes Infect; 2024 Dec; 13(1):2290841. PubMed ID: 38044868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
    Nathan A; Rossin EJ; Kaseke C; Park RJ; Khatri A; Koundakjian D; Urbach JM; Singh NK; Bashirova A; Tano-Menka R; Senjobe F; Waring MT; Piechocka-Trocha A; Garcia-Beltran WF; Iafrate AJ; Naranbhai V; Carrington M; Walker BD; Gaiha GD
    Cell; 2021 Aug; 184(17):4401-4413.e10. PubMed ID: 34265281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
    Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
    Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination.
    Geanes ES; LeMaster C; Fraley ER; Khanal S; McLennan R; Grundberg E; Selvarangan R; Bradley T
    Sci Rep; 2022 Apr; 12(1):6496. PubMed ID: 35444221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
    Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.